← Leaderboards
Judith A Steen
Boston Children'S Hospital
$11,275,952
Attributed
$22,632,613
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,632,613 · 7
By mechanism
R01$8,512,591 · 3
U01$7,788,010 · 1
UG3$3,635,845 · 1
UH3$2,548,234 · 1
P30$147,933 · 1
Top collaborators
- Dennis William Dickson6 shared
- Gerard David Schellenberg6 shared
- Li-San Wang6 shared
- Anthony William Paul Fitzpatrick5 shared
- Gabriel Kreiman5 shared
- Leonard Petrucelli5 shared
- Daniel H Geschwind4 shared
- Giovanni Coppola2 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Manasvi S. Shah$181,286
- Helen B. Tager-Flusberg$19,144,713
- Gabriel Kreiman$11,589,429
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPhenotypeProteomicsMass Spectrum AnalysisNeuronsPathologyNerve DegenerationPathologicTau ProteinsAffectValidationBrain TissueBrainProteinsSiteComplexIn VivoBiologyBaseBioinformaticsMapsCellsProgressive Supranuclear PalsyPost-Translational Protein Processing
Grant awards (27)
Integrated Platform to study Neurodegeneration in Alzheimerâs Disease$762,780
R01 · FY2025 · AG · contact PI
Integrated Platform to study Neurodegeneration in Alzheimerâs Disease$778,347
R01 · FY2024 · AG · contact PI
Integrated Platform to study Neurodegeneration in Alzheimerâs Disease$778,347
R01 · FY2023 · AG · contact PI
Patient-Based Structural Biology of Tauopathies and TDP-43 Proteinopathies using Cryo-Electron Microscopy and Mass Spectrometry$1,629,162
U01 · FY2022 · NS
Integrated Platform to study Neurodegeneration in Alzheimerâs Disease$778,347
R01 · FY2022 · AG · contact PI
Patient-Based Structural Biology of Tauopathies and TDP-43 Proteinopathies using Cryo-Electron Microscopy and Mass Spectrometry$1,629,162
U01 · FY2021 · NS
Impact of coding and non-coding variation in progressive supranuclear palsy$883,926
UH3 · FY2021 · NS
Impact of coding and non-coding variation in progressive supranuclear palsy$780,382
UH3 · FY2021 · NS
Integrated Platform to study Neurodegeneration in Alzheimerâs Disease$778,347
R01 · FY2021 · AG · contact PI
Patient-Based Structural Biology of Tauopathies and TDP-43 Proteinopathies using Cryo-Electron Microscopy and Mass Spectrometry$1,629,162
U01 · FY2020 · NS
Impact of coding and non-coding variation in progressive supranuclear palsy$883,926
UH3 · FY2020 · NS
Patient-Based Structural Biology of Tauopathies and TDP-43 Proteinopathies using Cryo-Electron Microscopy and Mass Spectrometry$1,434,762
U01 · FY2019 · NS
Impact of coding and non-coding variation in progressive supranuclear palsy$1,194,205
UG3 · FY2019 · NS
Patient-Based Structural Biology of Tauopathies and TDP-43 Proteinopathies using Cryo-Electron Microscopy and Mass Spectrometry$1,465,762
U01 · FY2018 · NS
Impact of coding and non-coding variation in progressive supranuclear palsy$1,198,968
UG3 · FY2018 · NS
Proteogenomics to characterize novel non-coding and extragenic translation$546,581
R01 · FY2018 · GM · contact PI
Proteogenomics to characterize novel non-coding and extragenic translation$250,000
R01 · FY2018 · GM · contact PI
Impact of coding and non-coding variation in progressive supranuclear palsy$1,242,672
UG3 · FY2017 · NS
Proteogenomics to characterize novel non-coding and extragenic translation$546,581
R01 · FY2017 · GM · contact PI
Proteogenomics to characterize novel non-coding and extragenic translation$546,581
R01 · FY2016 · GM · contact PI
Proteogenomics to characterize novel non-coding and extragenic translation$545,039
R01 · FY2015 · GM · contact PI
Regulation of SMN and Identification of its Downstream Target$444,456
R01 · FY2014 · NS · contact PI
Regulation of SMN and Identification of its Downstream Target$433,236
R01 · FY2013 · NS · contact PI
Regulation of SMN and Identification of its Downstream Target$442,245
R01 · FY2012 · NS · contact PI
Regulation of SMN and Identification of its Downstream Target$440,127
R01 · FY2011 · NS · contact PI
Proteomics Core$147,933
P30 · FY2011 · HD · contact PI
Regulation of SMN and Identification of its Downstream Target$441,577
R01 · FY2010 · NS · contact PI